5/3
12:53 pm
gmab
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/2
11:07 am
gmab
Genmab Announces Financial Results for the First Quarter of 2024 [Yahoo! Finance]
Low
Report
Genmab Announces Financial Results for the First Quarter of 2024 [Yahoo! Finance]
5/2
11:01 am
gmab
Genmab Announces Financial Results for the First Quarter of 2024
Low
Report
Genmab Announces Financial Results for the First Quarter of 2024
5/1
10:42 am
gmab
Genmab: A Complicated Tale [Seeking Alpha]
Low
Report
Genmab: A Complicated Tale [Seeking Alpha]
4/30
08:12 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
4/30
06:31 am
gmab
Pfizer, Genmab cervical cancer therapy wins full FDA approval [Seeking Alpha]
Low
Report
Pfizer, Genmab cervical cancer therapy wins full FDA approval [Seeking Alpha]
4/29
06:42 pm
gmab
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]
Medium
Report
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]
4/29
06:40 pm
gmab
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Medium
Report
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
4/29
06:40 pm
gmab
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Medium
Report
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
4/29
06:28 am
gmab
Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade) [Seeking Alpha]
Low
Report
Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade) [Seeking Alpha]
4/10
02:32 pm
gmab
Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale [BNN Bloomberg (Canada)]
Low
Report
Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale [BNN Bloomberg (Canada)]
4/7
06:38 am
gmab
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion [Seeking Alpha]
Low
Report
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion [Seeking Alpha]
4/4
12:33 pm
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
4/3
04:25 am
gmab
Genmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash deal [Seeking Alpha]
Low
Report
Genmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash deal [Seeking Alpha]
4/3
03:50 am
gmab
Denmark's Genmab to acquire ProfoundBio for $1.8 billion [Reuters]
Low
Report
Denmark's Genmab to acquire ProfoundBio for $1.8 billion [Reuters]
4/3
02:56 am
gmab
Genmab Buys Ovarian Cancer Drug Developer for $1.8 Billion [BNN Bloomberg (Canada)]
Low
Report
Genmab Buys Ovarian Cancer Drug Developer for $1.8 Billion [BNN Bloomberg (Canada)]
4/3
01:39 am
gmab
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio [Yahoo! Finance]
Low
Report
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio [Yahoo! Finance]
4/3
01:35 am
gmab
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Low
Report
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
4/3
01:34 am
gmab
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Low
Report
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
3/27
08:08 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
3/26
11:13 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "underweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $32.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "underweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $32.00 price target on the stock.
3/26
09:33 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $50.00 price target on the stock.
3/25
09:38 am
gmab
Transactions in Connection with Share Buy-back Program [Yahoo! Finance]
Low
Report
Transactions in Connection with Share Buy-back Program [Yahoo! Finance]
3/15
09:29 am
gmab
Genmab announces ~$510M worth of share buybacks [Seeking Alpha]
Low
Report
Genmab announces ~$510M worth of share buybacks [Seeking Alpha]
3/13
04:56 pm
gmab
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab [Yahoo! Finance]
Low
Report
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab [Yahoo! Finance]